Register for this webinar to hear experts from MRN and Magenta Therapeutics as they share their best practices in planning, implementation and integrations — things you need to know to successfully run a decentralized clinical trial.

TORONTO (PRWEB)
May 28, 2021

Decentralized trials have proven to allow continued recruitment and retention of patients, keeping trials and patients’ wellbeing on track, even during a pandemic.

For the past 15 years, MRN has been driving the successful implementation of decentralized clinical trials for the pharmacautical industry. MRN has spent over a decade advocating for a decentralized, patient-friendly approach to clinical trials, bringing trial visits to the patient in their own home and community. MRN successfully delivered a historical record number of visits in response to our most challenging chapter, helping their clients successfully navigate the Covid-19 pandemic.

Both existing and new clients turned to MRN to help rescue their trials from imminent failure. New, rapid response teams and processes were created and implemented across the MRN business to continue to support trials. MRN service offerings expanded, and they continued to strengthen their alliances with suppliers.

Register for this webinar to hear experts from MRN and Magenta Therapeutics as they share their best practices in planning, implementation and integrations — things you need to know to successfully run a decentralized clinical trial. You will get a view into the successes, challenges and lessons learned from both sides of the table. They will introduce participants to their learnings and experience running trials during a pandemic and share their insights to designing trials that can incorporate decentralized services.

Join Todd McGrath, Vice President, Global Head Project Management, MRN; and Alison Occhiuti, Associate Director, Clinical Operations, Magenta Therapeutics, for the live webinar on Wednesday, June 2, 2021 at 10am EDT (3pm BST/UK).

For more information, or to register for this event, visit How to Build a Successful Decentralized Clinical Trial and Avoid Common Mistakes.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Register for this webinar to hear about how the SynFini tools work independently and then how they fit together into seamless AI-data driven automated solutions for drug discovery and process development are presented.

TORONTO (PRWEB)
May 28, 2021

The rate of chemical discovery and development is hampered by the fact that chemistry is still inherently a manual process. In an effort to improve and accelerate the reproducibility and transferability of chemistry, we have developed an automation platform named SynFini™ that automates the design, reaction screening and optimization (RSO) and production of target molecules.

SynFini includes three core components. A computational tool, SynRoute, develops synthetic strategies for molecules of interest. A high throughput RSO platform, SynJet, enabled by inkjet printing uses statistical design of experiment (DoE) to validate these strategies. Automated analysis of the RSO results facilitates the preparation of digital synthesis protocols that can be downloaded to a bench top multistep synthesizer, called AutoSyn. AutoSyn is a flow chemistry workstation capable of performing synthesis routes at the milligram to gram scale while automatically capturing all synthesis parameters in real-time into a new automated chemistry reaction database.

To accelerate multi-parametric optimization in drug discovery, artificial intelligence (AI) can be included to aid in the design, selection and prioritization of target structures with desired properties, and can be interfaced with SynFini automated synthesis and bioassay testing for rapid ‘design-make-test’ cycles. We are also using the core SynFini components for process development to provide synthetic route and kinetic data to create ‘digital twin’ computer models of continuous manufacturing systems for APIs that enable direct translation of scale-up from bench to multi-kg/hr production in one step.

Register for this webinar to hear about how the SynFini tools work independently and then how they fit together into seamless AI-data driven automated solutions for drug discovery and process development are presented.

Join Nathan Collins, Chief Strategy Officer, SRI Biosciences, A Division of SRI International, for the live webinar on Wednesday, June 16, 2021 at 1pm EDT (10am PDT).

For more information, or to register for this event, visit Combining AI and Automation in the SynFini™ Platform to Accelerate Small Molecule Drug Discovery.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

“We hope to channel Irma’s extensive business development experience to grow our organization to a new level for our healthcare partners and the patients they serve,” said Bill Shanahan, CEO of Covelo Group.

SAN FRANCISCO (PRWEB)
May 28, 2021

Covelo Group, a leading healthcare staffing agency, announced today it hired staffing executive Irma Park to join the senior leadership team as VP of National Accounts. Irma’s responsibilities will focus on driving strategic market entry and business development efforts in new and existing markets.

Irma brings over 20 years of healthcare staffing experience, most recently serving as the VP of Nursing and Client Relations for KPG Healthcare. She gained most of her staffing expertise by leading business development teams in her previous roles, which led to long-standing national partnerships. Irma’s 10-years in workforce management for MedAssets, a vendor management company acquired by Vizient, brings a fresh perspective to Covelo Group, tying together two key facets of the business.

“We hope to channel Irma’s extensive business development experience to grow our organization to a new level for our healthcare partners and the patients they serve,” said Bill Shanahan, CEO of Covelo Group. “Our communities continue to see a demand for qualified clinical and non-clinical hospital staff. With Irma on board, we look forward to developing new talent solutions for rising needs within the healthcare industry.”

“I take pride in my ability to align business objectives with partnership requirements, making my relationships meaningful for both parties,” said Irma Park, VP of National Accounts. “I am honored to have the opportunity to work with Covelo Group and look forward to establishing how we will remain highly valued by those we serve.”

Since March 2020, Covelo Group has acquired accounts in the Midwest and Southwest regions, expanding its operations to major metropolitan markets such as Chicago and Denver. This expansion was driven out of an effort to deliver effective operational solutions during a turbulent year.

As an industry leader in allied health, healthcare administration, nursing, and environmental services staffing, Covelo Group specializes in aligning the right candidate to a client’s need to quickly fill critical positions. Covelo Group is wholly owned by ZOE Holding Company. For more information, visit CoveloGroup.com.

About Covelo Group

At Covelo Group, our highly personal approach to recruitment focuses on building great relationships with candidates and healthcare organizations. Over the last 17 years, we’ve placed thousands of clinical and non-clinical healthcare professionals throughout the U.S. With that experience comes unparalleled reliability, accountability, and expertise. The company has been named Best of Staffing for Client Satisfaction three years in a row. Covelo Group is part of the ZOE Holding Company family of businesses. Learn more about our current job opportunities at CoveloGroup.com or follow us on LinkedIn.

About ZOE Holding

Headquartered in Scottsdale, Ariz., ZOE Holding Company is a growing multi-state enterprise with multiple subsidiaries all focused on one thing: Creating Opportunity. ZOE Holding Company employs thousands of talented individuals through its diversified staffing businesses and is the operations, strategy, and financial engine supporting our offices throughout the country. This support allows our subsidiary companies to focus on providing outstanding staffing services to companies throughout the US. For more information, please connect with us on LinkedIn or visit our website at ZOEHolding.com.

Share article on social media or email:

PRN Expansion to California: Mills Clinical Research

“Dr. Mills was an obvious fit to join our team, given his extensive experience in the infectious disease space and his reputation for high quality clinical research,” said Jason Roth, Vice President of PRN.

AUSTIN, Texas (PRWEB)
May 28, 2021

The COVID-19 pandemic has brought challenges and opportunities to the clinical research industry. Within every region of the USA, the acceleration of R&D activities by vaccine developers has translated to an increased need for experienced research investigators.

In 2020, Platinum Research Network (PRN) and its member companies pioneered new technologies and methods to scale up delivery of predictable enrollment and high-quality data – all to support the rapid development of COVID-19 vaccines. The network is known for its geographic diversity providing research services in a mix of urban, suburban, and rural site locations. With the addition of Mills Clinical Research in California, PRN now provides those services from sea to shining sea.

Founded in 1999, Mills Clinical Research focuses on infectious diseases, vaccine trials, and men’s health. Located in Los Angeles, CA, Mills Clinical Research is led by Principal Investigator and CEO Dr. Anthony Mills. Dr. Mills, a pioneer in clinical research with a long history in advocating and helping reduce health inequalities, especially amongst black and brown and LGBTQ+ communities. As an HIV specialist, Dr. Mills built his clinical research operation to provide his patients with access to new medicines and preventives.

While the network provides expertise in multiple therapeutic areas, all PRN partners share a passion for prevention and treatment of Infectious Diseases. “Dr. Mills was an obvious fit to join our team, given his extensive experience in the infectious disease space and his reputation for high quality clinical research,” said Jason Roth, Vice President of PRN. “We are ecstatic that Dr. Mills and his clinical team have joined our research family.”

To date, Platinum Research Network research centers have enrolled more than 15,000 clinical trial participants into COVID-19 vaccine studies including adults, older adults, children, and pregnant patients. PRN Members include MedPharmics, Meridian Clinical Research, Sterling

Research Group, Sundance Clinical Research, Tekton Research, Ventavia Research Group – and now Mills Clinical Research.

Dr. Mills and Jason Roth are available for interview via video, phone, or any other platform.

For more information, contact: prnrequest@platinum-research.net

Share article on social media or email:

Dr. Tom Biernacki Foot Ankle Surgeon in Berkley Michigan

Dr. Tomasz Biernacki DPM states “We believe health care is changing rapidly. Patients want more options beyond just coming to the office. People need better service and convenience to start feeling better and if we can help at a lower cost burden, then we would love to help!”

BERKLEY, Mich. (PRWEB)
May 28, 2021

Prime Foot & Ankle Specialists is based in Berkley Michigan providing podiatrists and foot doctor office visits, telehealth & home care options. Podiatrist Tomasz Biernacki DPM has joined the Prime Foot & Ankle Specialists team.

Dr. Tom Biernacki states “I am incredibly happy to be joining the team and am overly excited about the excellent patient care that the podiatrists here are already providing. They are forward thinking with podiatrist telehealth visits, minimally invasive surgery and podiatrist home care for those that cannot make it into clinic.”

Prime Foot & Ankle Specialists prides itself as providing modern and advanced podiatrist care. The foot doctors and podiatrists at Prime Foot & Ankle Specialists will provide care in the office setting allowing in office appointments, consultations for minimally invasive foot and ankle surgeries, as well foot care for those who cannot take care of their own feet.

A unique feature of Prime Foot & Ankle Specialists is that they are one of the leaders in southeast Michigan in house call podiatrist care. The foot doctors and podiatrists have been providing podiatrist home care visits, podiatrist house call visits and telehealth options for numerous years.

Prime Foot & Ankle Specialists include Dr. Tomasz Biernacki DPM, Dr. Jeffrey Klein DPM, Dr. Robert Strasberger DPM, Dr. Andrew Thompson DPM, Dr. Herbert Bircoll DPM, Dr. Gerald Gold DPM & Dr. Leslie Joseph DPM.

Dr. Tomasz Biernacki DPM states “We believe health care is changing rapidly. Patients want more options beyond just coming to the office. People need better service and convenience to start feeling better and if we can help at a lower cost burden, then we would love to help!”

Prime Foot & Ankle Specialists have been providing care to the Metro Detroit Area for over 30 years. The headquarters are in Berkley Michigan.

Share article on social media or email:

For more than three decades, Dr. Granpeesheh and CARD have been dedicated to enhancing treatment efficacy through evidence-based clinical practices, research, and technology development.

PLANO, Texas (PRWEB)
May 27, 2021

The founder of the Center for Autism and Related Disorders (CARD), Doreen Granpeesheh, Ph.D., BCBA-D, has partnered with the Association for Behavior Analysis International (ABAI) to establish The Doreen Granpeesheh Fund to enhance autism treatment by encouraging collaboration across disciplines. While individuals with autism spectrum disorder (ASD) often receive services from many different treatment providers, interdisciplinary collaboration is not common practice. The purpose of the endowment is to bridge the gap between behavioral and biomedical treatments for ASD.

Applied behavior analysis (ABA) is a well-established treatment for ASD, which involves the application of behavioral principles to reduce challenging behaviors and promote skill acquisition. If left untreated, co-occurring medical conditions prevalent among individuals with ASD, including sleep problems, gastrointestinal problems, anxiety, and seizures, may exacerbate challenging behaviors and diminish treatment response. The multidisciplinary treatment approach, which is the focus of The Doreen Granpeesheh Fund, cares for the whole patient, optimizing treatment efficacy and improving patient outcomes.

In a previous news release, ABAI stated, “We are most grateful to Doreen Granpeesheh for her generous donation of $100,000 to establish a fund in her name. The Doreen Granpeesheh Fund will be dedicated to introducing our community to other disciplines to develop and collaborate on more comprehensive interventions to understand and treat autism.”

For the first time, the fund will sponsor presentations from biomedical experts at ABAI’s annual conventions, among other initiatives, to encourage interdisciplinary collaboration. By improving behavioral analysts’ understanding of biomedical treatment practices, they will be better equipped to seek interdisciplinary collaboration when it is in the best interest of their patient.

“My endowment supports the establishment of ongoing training for behavior analysts on the medical and biological complexities of autism. I hope these annual lectures will bridge the gap between biomedical and behavioral interventions,” said Dr. Granpeesheh.

This generous donation exemplifies Dr. Granpeesheh’s unwavering commitment to advance ABA treatment and improve the lives of individuals with ASD. For more than three decades, Dr. Granpeesheh and CARD have been dedicated to enhancing treatment efficacy through evidence-based clinical practices, research, and technology development. Cultivating a whole-patient treatment philosophy is another critical step toward helping individuals with ASD achieve their full potential.

The first biomedical presentation sponsored by The Doreen Granpeesheh Fund will take place at ABAI’s upcoming 47th Annual Convention. During the presentation, The Medical and Biological Complexity of Autism, Dr. Richard Frye, MD., Ph.D., will discuss medical comorbidities of ASD that may hinder successful habilitation if left untreated. The online presentation will take place on Sunday, May 30, from 11 a.m. to 11:50 a.m. EDT.

About Center for Autism and Related Disorders (CARD)

CARD treats individuals of all ages diagnosed with autism spectrum disorder (ASD) at treatment centers around the globe. CARD was founded in 1990 by leading autism expert and clinical psychologist Doreen Granpeesheh, Ph.D., BCBA-D. CARD treats individuals with ASD using the principles of applied behavior analysis (ABA), which is empirically proven to be the most effective method for treating individuals with ASD and recommended by the American Academy of Pediatrics and the US Surgeon General. CARD employs a dedicated team of trained professionals across the nation and internationally. For more information, visit centerforautism.com.

Share article on social media or email: